Chemical compounds

US11014908B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Ariamala Gopalsamy · Lexington, US
• Arjun Venkat Narayanan · Cambridge, US
• Agustin Casimiro-Garcia · Concord, US
• Chulho Choi · Mystic, US
• David Hepworth · Concord, US
• David W. Piotrowski · Waterford, US
• Hatice Gizem Yayla · Mystic, US
• Jayasankar Jasti · East Lyme, US
• Lee Richard Roberts · Chatham, GB
• Lyn Howard Jones · Canterbury, GB
• Mihir Dineshkumar Parikh · Davisville, US
• Ming Zhu Chen · Mystic, US
• Olugbeminiyi Omezia Fadeyi · Harvard, US
• Ralph P. Robinson · Gales Ferry, US
• Robert L. Dow · Waterford, US
• Shawn Cabral · Groton, US

Key dates

• Filing date: Nov 26, 2019
• Grant date: May 25, 2021
• Expiry date: Nov 26, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).